Results 181 to 190 of about 2,280,070 (229)

Willingness to Receive Latent Tuberculosis Infection Treatment Among Migrants in Tijuana, Baja California, Mexico. [PDF]

J Immigr Minor Health
Garfein RS, Seifert M, Abramovitz D, Bojorquez-Chapela I, Harvey-Vera A, Sepulveda J, Strathdee SA.   +6 more
europepmc   +1 more source

Uncovering hidden risk: The role of social history in identifying possible latent tuberculosis infection in primary care. [PDF]

J Family Med Prim Care
Rahman M, Ferreiro FL.
europepmc   +1 more source

Effect of PPD inoculation on serum cytokine profiles in latent tuberculosis infection populations. [PDF]

Front Cell Infect Microbiol
Chang W, Sun D, Zhang Y, Ji S, Wang S, Wang W, Ma X, Zheng D, Su R, Zhu Y, Shi J, Diao L.   +11 more
europepmc   +1 more source

Pan-Immune-Inflammatory value and risk of latent tuberculosis infection. [PDF]

Sci Rep
Ye X, Kang X, Zhang H, Wang W.
europepmc   +1 more source

Preferences for treatment for latent tuberculosis infection in primary care among people in the United States at increased risk of tuberculosis: a pilot survey

Aschmann HE, Tang AS, Lee M, Salcedo KL, Murrill MT, Chen G, Ouyang Y, Lui K, Rahman M, Flood J, Kerkhoff AD, Lin TK, Shete PB, the Tuberculosis Epidemiologic Studies Consortium.   +13 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Latent Tuberculosis Infection

New England Journal of Medicine, 2021
Susan E Dorman, Maunank Shah
exaly   +3 more sources

Management of Latent Tuberculosis Infection

JAMA - Journal of the American Medical Association, 2023
This JAMA Insights Clinical Update examines treatment recommendations and therapy options among adults with latent tuberculosis infection.
Daria Szkwarko
exaly   +3 more sources

Treatment of Latent Tuberculosis Infection

Annals of Internal Medicine, 2015
possible comparisons, 42 (40%) were compared directly. Compared with placebo, isoniazid for 6 months (odds ratio [OR], 0.64 [95% credible interval {CrI}, 0.48 to 0.83]) or 12 months or longer (OR, 0.52 [CrI, 0.41 to 0.66]), rifampicin for 3 to 4 months (OR, 0.41 [CrI, 0.18 to 0.86]), rifapentine-isoniazid (OR, 0.61 [CrI, 0.29 to 1.22]), and rifampicin ...
Dominik, Zenner, Helen R, Stagg, Ross J, Harris, Ibrahim, Abubakar   +3 more
  +7 more sources